Computer device and computer readable storage medium for screening susceptible population for acute mountain sickness

Through computer devices and programs, allelic T information of SNP rs12086322 locus is used to screen individuals susceptible to acute altitude disease, solving the problem of how to effectively screen and predict the susceptibility of acute altitude disease, and achieving susceptibility to acute altitude disease Quick and accurate assessment.

CN118737271BActive Publication Date: 2024-11-29GENERAL HOSPITAL OF PLA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411230156.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-29
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

How to screen individuals with susceptibility to acute altitude disease or predict subjects' susceptibility to acute altitude disease.

Method used

Through a computer device and a computer-readable storage medium, information is received on whether the subject's SNP rs12086322 locus carries allele T, and a computer program is executed to output the result information to determine whether the subject is a susceptible individual to acute altitude sickness.

Benefits of technology

Screening and susceptibility predictions for individuals susceptible to acute altitude disease are achieved, providing a rapid and accurate method to assess individuals' risk for acute altitude disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
Patent Text Reader

Abstract

The present invention discloses a computer device and a computer-readable storage medium for screening a population susceptible to acute mountain sickness. The present invention provides a computer device, comprising a memory, a processor, and a computer program stored on the memory, characterized in that: the processor executes the computer program to implement the following steps: s1, data reception: receiving information on whether the subject's SNP rs12086322 site carries allele T, and obtaining sample data; s2, result output: outputting result information from the computer based on the sample data, the result information being whether the subject is an individual susceptible to acute mountain sickness. The computer device and computer-readable storage medium provided by the present invention can be used to avoid or reduce the occurrence of acute mountain sickness.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical care informatics, and in particular relates to a computer device and a computer-readable storage medium for screening a population susceptible to acute mountain sickness. Background Art

[0002] The plateau has the characteristics of high altitude, low air pressure, special landform, high oxygen content, strong ultraviolet radiation, and large temperature difference between day and night. People who usually live in the plains will experience symptoms such as headache, dizziness, nausea, fatigue, and sleep disorders when they suddenly go to the plateau (generally above 3000m above sea level), and develop acute mountain sickness (AMS), which seriously affects the body's physical and mental health, quality of life and work ability.

[0003] With the increasing incidence of AMS in plateau areas, as well as the needs of social development and military operations, more and more researchers have conducted a series of studies on the occurrence of AMS. It was found that acute mountain sickness is the result of the combined effects of genetic and environmental factors, and has genetic susceptibility, that is, the probability of AMS in a hypoxic environment is closely related to individual susceptibility genes. Therefore, susceptibility genes may be used as an important molecular marker to prevent and diagnose diseases, assess the severity of AMS, and provide effective treatment methods. Summary of the invention

[0004] The technical problem to be solved by the present invention is how to screen individuals susceptible to acute mountain sickness or how to predict the susceptibility of subjects to acute mountain sickness.

[0005] The object of the present invention is to provide a computer device and a computer-readable storage medium for screening a population susceptible to acute mountain sickness.

[0006] The present invention provides a computer device, comprising a memory, a processor and a computer program stored in the memory, wherein the processor executes the computer program to implement the following steps:

[0007] s1. Data reception: receiving information on whether the subject's SNP rs12086322 site carries allele T, and obtaining sample data;

[0008] s2. Result output: Outputting result information from the computer based on the sample data, wherein the result information indicates whether the subject is susceptible to acute mountain sickness.

[0009] The logical judgment rule for outputting the result information from the computer based on the sample data is: if the subject carries allele T at the SNPrs12086322 site, the subject is an individual susceptible to acute mountain sickness; if the subject does not carry allele T at the SNPrs12086322 site, the subject is not susceptible to acute mountain sickness.

[0010] The present invention also provides a computer program product, including a computer program, characterized in that: when the computer program is executed by a processor, the above-mentioned steps s1 and s2 are implemented.

[0011] The present invention further provides a computer-readable storage medium on which a computer program is stored, wherein the computer program implements the above-mentioned steps s1 and s2 when executed by a processor.

[0012] The present invention also provides a device for screening individuals susceptible to acute mountain sickness, characterized in that the device comprises the following modules:

[0013] M1, data receiving module: used to receive information about whether the subject's SNP rs12086322 site carries allele T, and obtain sample data;

[0014] M2. Result output module: used to output result information from a computer based on the sample data, wherein the result information is whether the subject is an individual susceptible to acute mountain sickness.

[0015] The logical judgment rule for outputting the result information from the computer based on the sample data is: if the subject carries allele T at the SNPrs12086322 site, the subject is an individual susceptible to acute mountain sickness; if the subject does not carry allele T at the SNPrs12086322 site, the subject is not susceptible to acute mountain sickness.

[0016] The present invention also provides a method for screening individuals susceptible to acute mountain sickness, characterized in that:

[0017] The method comprises the following steps:

[0018] Receive information about whether the subject's SNP rs12086322 site carries allele T, and obtain sample data;

[0019] Result information is output from the computer based on the sample data, wherein the result information indicates whether the subject is an individual susceptible to acute mountain sickness.

[0020] The logical judgment rule for outputting the result information from the computer based on the sample data is: if the subject carries allele T at the SNPrs12086322 site, the subject is an individual susceptible to acute mountain sickness; if the subject does not carry allele T at the SNPrs12086322 site, the subject is not susceptible to acute mountain sickness.

[0021] The present invention also provides a device, which is a device for comparing the susceptibility of subjects to acute mountain sickness, characterized in that the device comprises the following modules:

[0022] M3, data receiving module: used to receive information about whether the subject's SNP rs12086322 site carries allele T, and obtain sample data;

[0023] M4. Result output module: used to output result information from a computer based on the sample data, wherein the result information is that the susceptibility to acute mountain sickness of subjects carrying allele T at the SNP rs12086322 site is higher than the susceptibility to acute mountain sickness of subjects not carrying allele T at the SNP rs12086322 site.

[0024] The present invention also provides a method for comparing the susceptibility of subjects to acute mountain sickness, characterized in that:

[0025] The method comprises the following steps:

[0026] Receive information about whether the subject's SNP rs12086322 site carries allele T, and obtain sample data;

[0027] Result information is output from a computer based on the sample data, wherein the result information indicates that the susceptibility to acute mountain sickness of subjects carrying the T allele at the SNP rs12086322 site is higher than the susceptibility to acute mountain sickness of subjects not carrying the T allele at the SNP rs12086322 site.

[0028] Specifically, the subjects are two or more persons.

[0029] The present invention also provides the use of a primer set or a primer pair in the preparation of a product. The present invention also provides a product, which includes a primer set or a primer pair. The function of the product is to screen individuals susceptible to acute mountain sickness or to compare the susceptibility of subjects to acute mountain sickness. The primer set consists of three primers, which are the single-stranded DNA molecule shown in SEQ ID NO: 1, the single-stranded DNA molecule shown in SEQ ID NO: 2, and the single-stranded DNA molecule shown in SEQ ID NO: 3. The primer pair consists of two primers, which are the single-stranded DNA molecule shown in SEQ ID NO: 4 and the single-stranded DNA molecule shown in SEQ ID NO: 5. If the subject's SNP rs12086322 site carries allele T, the subject is an individual susceptible to acute mountain sickness; if the subject's SNP rs12086322 site does not carry allele T, the subject is not an individual susceptible to acute mountain sickness. The susceptibility to acute mountain sickness of the subject carrying the T allele at the SNP rs12086322 site is higher than the susceptibility to acute mountain sickness of the subject whose result information is that the SNP rs12086322 site does not carry the T allele.

[0030] Specifically, based on SNP rs12086322, the subject's genotype is TT or TC or CC.

[0031] SNP rs12086322 is located in human genomic DNA, and its position corresponds to the 301st nucleotide in sequence 6 of the sequence list, and is represented by Y. Y represents T or C.

[0032] Any of the above subjects may be Chinese.

[0033] Any of the above-mentioned subjects may be Chinese Han nationality.

[0034] Any of the above-mentioned subjects may be Chinese Han males.

[0035] Any of the above subjects may be Chinese living in plain areas.

[0036] Any of the above-mentioned subjects may be Chinese Han people living in plain areas.

[0037] Any of the above-mentioned subjects may be Chinese Han males living in plain areas.

[0038] Any of the above subjects may be Chinese who have arrived in plateau areas from plain areas.

[0039] Any of the above-mentioned subjects may be Chinese Han people who move from plain areas to plateau areas.

[0040] Any of the above-mentioned subjects may be Chinese Han males who move from plain areas to plateau areas.

[0041] Any of the above subjects may be Chinese who plan to go to high-altitude areas from plain areas.

[0042] Any of the above-mentioned subjects may be Chinese Han people who are expected to move from a plain area to a plateau area.

[0043] Any of the above-mentioned subjects may be Chinese Han males who are expected to move from plain areas to plateau areas.

[0044] Any of the above-mentioned plateau areas may be the Qinghai-Tibet Plateau.

[0045] Any of the plateau areas mentioned above may be the Lhasa area of ​​the Qinghai-Tibet Plateau.

[0046] Any of the above-mentioned plateau areas may be the Ali region, Luhuo region, Ganzi region, Kangding region or Xinduqiao region of the Qinghai-Tibet Plateau.

[0047] The inventors of the present invention found that based on SNP rs12086322, subjects carrying allele T are susceptible to acute mountain sickness, and the risk of AMS in subjects carrying allele T is higher than that in subjects not carrying allele T. In Example 3 and Example 4, the present invention uses samples of different populations as examples to exemplarily show the genotype distribution frequency data in the acute mountain sickness patient group and the normal population. Based on the above findings, the inventors of the present invention developed the above-mentioned computer device and computer-readable storage medium.

[0048] The computer device and computer-readable storage medium provided by the present invention can be used to avoid or reduce the occurrence of acute mountain sickness. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 A computer flow chart. DETAILED DESCRIPTION

[0050] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0051] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0052] p-value:Person test. lnBeta=OR, OR: odds ratio.

[0053] Ethics statement: Each subject signed an informed consent form, and this study was approved by the Medical Ethics Committee of the PLA General Hospital. The 2018 version of the Louis Lake Score was used to assess acute mountain sickness (AMS), and all patients with AMS had a score of ≥3.

[0054] Example 1: Screening for SNPs associated with the risk of acute mountain sickness

[0055] The matched groups consisted of patients with acute mountain sickness and corresponding normal people.

[0056] Multiple paired groups were established, and a large number of whole genome sequencing and sequence comparison analysis were performed to obtain a large number of differential SNPs. The allele frequency and genotype frequency of each differential SNP in the acute mountain sickness patient group and the corresponding normal population were verified in turn for association analysis.

[0057] SNP rs12086322, i.e., the SNP numbered rs12086322 in NCBI, is specifically located at position 3449750 (GRCh38.p14) of human chromosome 1, and the polymorphic form is T / C. In human genomic DNA, SNP rs12086322 and its surrounding nucleotides are shown in sequence 6 of the sequence listing (SNP rs12086322 is the 301st nucleotide in sequence 6 of the sequence listing, represented by Y).

[0058] No clinical diagnostic use of SNP rs12086322 has been found in the prior art.

[0059] The inventors found through the aforementioned extensive work that SNP rs12086322 is correlated with the risk of acute mountain sickness, and subjects carrying the allele T have a higher risk of acute mountain sickness.

[0060] Example 2: Establishment of a method for detecting the genotype of a subject based on SNP rs12086322

[0061] 1. Take peripheral blood from the subjects and extract genomic DNA.

[0062] 2. Using the genomic DNA extracted in step 1 as a template, perform PCR amplification using specific primer pairs.

[0063] The specific primer pair consists of primer F1 and primer R1.

[0064] Primer F1 (SEQ ID NO: 1): 5'-ACGTTGGATGCACCACCCAAGGATTTATAGG-3';

[0065] Primer R1 (SEQ ID NO: 2): 5'-ACGTTGGATGAGGCTTGTCTCGAACTTCTG-3'.

[0066] PCR amplification was performed in a 384-well plate, with one reaction system in each well.

[0067] The composition of the PCR amplification reaction system (5 μL): 0.5 μL 10× PCR buffer (Agena Bioscience, catalog number 11327), 0.4 μL 25 mM MgCl2 solution, 0.1 μL 25 mM dNTP mix, genomic DNA, HotStart Taq DNA polymerase, primer F1, primer R1, and the volume is made up with ultrapure water. In the 5 μL system, the content of genomic DNA is 20-50 ng, the content of HotStart Taq DNA polymerase is 0.5 U, the content of primer F1 is 0.5 pmol, and the content of primer R1 is 0.5 pmol.

[0068] The reaction program of PCR amplification was as follows: 94°C for 4 minutes; 94°C for 20 seconds, 56°C for 30 seconds, 72°C for 1 minute, 45 cycles; 72°C for 3 minutes; and 4°C hold.

[0069] 3. Perform alkaline phosphatase treatment (to remove free dNTPs in the system).

[0070] Take the 384-well plate that has completed step 2, prepare the reaction system and then carry out the reaction.

[0071] The composition of the reaction system (7 μL): 5 μL of the product solution obtained in step 2, 0.3 μL of SAP, 0.17 μL of SAPbuffer, and 1.53 μL of ultrapure water. The SAP content in the reaction system was 0.073 U / μL.

[0072] SAP (shrimp alkaline phosphatase), SAP buffer, iPlex Enzyme (single base extension reaction enzyme), and iPlex Buffer Plus (single base extension reaction buffer) are all components of the kit. Commercial information of the kit: Agena Bioscience, catalog number 10165.

[0073] Reaction conditions: 37°C for 40 minutes; 85°C for 5 minutes; maintain at 4°C.

[0074] 4. Perform single base extension.

[0075] Take the 384-well plate that has completed step 3, prepare the reaction system, and then perform a single base extension reaction.

[0076] The composition of the single base extension reaction system (10 μL): 7 μL of the product solution obtained in step 3, 0.3 μL of the single base extension reaction enzyme, 0.17 μL of the single base extension reaction buffer, 1 μL of the single base extension primer, and 1.53 μL of ultrapure water. In the single base extension reaction system, the content of the single base extension primer is 5 μmol, and the content of the single base extension reaction enzyme is 0.142 U / μL.

[0077] Single base extension primer (SEQ ID NO: 3): 5'-GTGGACTCAGACTGAAGCA-3'.

[0078] The reaction procedure for single base extension is as follows:

[0079] ①94℃ 30 seconds;

[0080] ②94℃ 5 seconds;

[0081] ③52℃ 5 seconds, 80℃ 5 seconds, 5 cycles;

[0082] ④94℃ 5 seconds, 52℃ 5 seconds, 80℃ 5 seconds, 40 cycles;

[0083] ⑤72℃ 3 minutes;

[0084] ⑥Maintain at 4℃.

[0085] 5. Perform resin purification.

[0086] Take the 384-well plate that has completed step 4, add 16 μl of water to each well, then add Clean Resin resin (Sequenom, USA) to each well, seal the film, rotate vertically at low speed for 30 minutes to allow the resin to fully contact with the reactants, then centrifuge to allow the resin to sink to the bottom of the well. The supernatant is the extension product after resin purification.

[0087] 6. Chip spotting.

[0088] The MassARRAY Nanodispenser RS1000 sample dispensing device (SEQUENOM) was started to transfer the extension product after resin purification to a 384-well SpectroCHIP (Sequenom) chip (SEQUENOM).

[0089] 7. Mass spectrometry detection.

[0090] The spotted SpectroCHIP chip was analyzed using MALDI-TOF, and the detection results were typed and output using TYPER 4.0 software (sequenom).

[0091] Example 3: Analysis of SNP rs12086322 and Susceptibility to Acute Mountain Sickness

[0092] Peripheral blood samples were obtained from Lhasa, Ali, Luhuo, Ganzi, Kangding and Xinduqiao from September 2020 to September 2023. 50 peripheral blood samples were obtained from 50 patients with acute mountain sickness, and another 232 peripheral blood samples were obtained from 232 normal people (non-acute mountain sickness patients). The 50 patients with acute mountain sickness and the 232 normal people were all unrelated Chinese Han males who had lived in the plains for a long time (long-term means more than 1 year) and had peripheral blood drawn after arriving in Lhasa, Ali, Luhuo, Ganzi, Kangding or Xinduqiao (above 2500m above sea level). All of them had no history of smoking and drinking, and no autoimmune-related diseases (such as vitiligo, psoriasis, type 1 diabetes, etc.), and no history of high altitude travel before.

[0093] The operation was performed according to the method of Example 2. The genotype of the subject based on SNP rs12086322 was detected.

[0094] Among the 50 patients with acute mountain sickness, there was 1 individual with genotype TT, 5 individuals with genotype TC, and 44 individuals with genotype CC, that is, 6 individuals carried the T allele (frequency was 12%), and 44 individuals did not carry the T allele (frequency was 88%). Among the 232 normal people, there was 0 individual with genotype TT, 19 individuals with genotype TC, and 213 individuals with genotype CC, that is, 19 individuals carried the T allele (frequency was 8.19%), and 213 individuals did not carry the T allele (frequency was 91.81%).

[0095] The experimental data were processed and counted using R 4.0.5 statistical software. After correction by generalized linear mixed model test, the significant P value of SNP rs12086322 and the population was 0.0015, and Beta was 1.242. The results showed that SNPrs12086322 was a SNP associated with acute mountain sickness, and the risk of AMS in subjects carrying allele T was higher than that in subjects not carrying allele T.

[0096] Example 4: Analysis of SNP rs12086322 and Susceptibility to Acute Mountain Sickness

[0097] Peripheral blood samples were obtained from Lhasa, Ali, Luhuo, Ganzi, Kangding and Xinduqiao from September 2020 to September 2023. 43 peripheral blood samples were obtained from 43 patients with acute mountain sickness, and another 284 peripheral blood samples were obtained from 284 normal people (non-acute mountain sickness patients). The 43 patients with acute mountain sickness and the 284 normal people were all unrelated Chinese Han males who had lived in the plains for a long time (long-term means more than 1 year) and had peripheral blood drawn after arriving in Lhasa, Ali, Luhuo, Ganzi, Kangding or Xinduqiao (above 2500m above sea level). All of them had no history of smoking and drinking, and no autoimmune-related diseases (such as vitiligo, psoriasis, type 1 diabetes, etc.), and no history of plateau travel before.

[0098] 1. Take peripheral blood from the subjects and extract genomic DNA.

[0099] 2. Using the genomic DNA extracted in step 1 as a template, perform PCR amplification using specific primer pairs.

[0100] The specific primer pair consists of primer F2 and primer R2.

[0101] Primer F2 (SEQ ID NO: 4): 5′-TGATGCCTGATACCGTCTC-3′;

[0102] Primer R2 (SEQ ID NO: 5): 5'-CAGTAAACTTGAAGCCAGGAC-3'.

[0103] 3. After completing step 2, the PCR amplification products were recovered and sequenced, and the genotype of the subject based on SNPrs12086322 was obtained according to the sequencing results.

[0104] Among the 43 patients with acute mountain sickness, there were 0 individuals with genotype TT, 9 individuals with genotype TC, and 34 individuals with genotype CC, that is, 9 individuals carried the T allele (frequency was 20.93%), and 34 individuals did not carry the T allele (frequency was 79.07%). Among the 284 normal people, there was 1 individual with genotype TT, 28 individuals with genotype TC, and 255 individuals with genotype CC, that is, 29 individuals carried the T allele (frequency was 10.21%), and 255 individuals did not carry the T allele (frequency was 89.79%).

[0105] The experimental data were processed and analyzed using R 4.0.5 statistical software. After correction by the generalized linear mixed model test, the significant P value of SNP rs12086322 and the population was <0.05 (p=0.028), and Beta was 0.631. Consistent with the results of Example 3, the risk of AMS in subjects carrying allele T was higher than that in subjects not carrying allele T.

[0106] The results of this example further illustrate that SNP rs12086322 is a risk site associated with acute mountain sickness, and can be used to screen individuals susceptible to acute mountain sickness, predict human susceptibility to acute mountain sickness, screen individuals carrying human acute mountain sickness susceptibility genes, and evaluate the risk of acute mountain sickness.

[0107] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. A device for comparing the susceptibility of subjects to acute mountain sickness, characterized in that: The device comprises the following modules: M3, data receiving module: used to receive information about whether the subject's SNP rs12086322 site carries allele T, and obtain sample data; the subject is more than two people; M4. Result output module: used to output result information from a computer based on the sample data, wherein the result information is that the susceptibility to acute mountain sickness of subjects carrying allele T at the SNP rs12086322 site is higher than the susceptibility to acute mountain sickness of subjects not carrying allele T at the SNP rs12086322 site.

Citation Information

Patent Citations

  • Gene screening method for high risk population with altitude sickness and relative gene diagnosing products thereof

    CN102559853A

  • Flow type liquid chip detection kit for acute mountain sickness heat shock protein 70 gene rs1008438 locus

    CN105385777A